Structure Therapeutics CSO exercises options, sells ADS

Accepted by SEC EDGAR 07/15/2026 - 06:57 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Structure Therapeutics Inc. chief scientific officer Xichen Lin exercised share options covering 23,634 Ordinary Shares at $0.34 per share, converted them into 7,878 American Depositary Shares, and sold all 7,878 ADS at weighted average prices of $50.7956 and $51.7088 per ADS under a Rule 10b5-1 trading plan entered into on March 26, 2026. Following these transactions, Lin holds 228,960 Ordinary Shares directly and options over 166,532 Ordinary Shares exercisable at $0.34 per share until September 10, 2029.

Insider Trade Summary 10b5-1

Net Seller: 7,878 shares

Net Sell 6 txns

Insider Lin Xichen

Role CHIEF SCIENTIFIC OFFICER

Sold 7,878 shs ($402K)

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy) F1, F3, F4	23,634	$0.00	$0.00
Conversion	American Depositary Shares F5, F6	7,878	$0.00	$0.00
Sale	American Depositary Shares F5, F7, F8, F9	6,278	$50.7956	$319K
Sale	American Depositary Shares F5, F7, F8, F10	1,600	$51.7088	$83K
Exercise	Ordinary Shares F1	23,634	$0.34	$8K
Conversion	Ordinary Shares F2	23,634	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 166,532 contracts (Direct); American Depositary Shares — 0 contracts (Direct); Ordinary Shares — 228,960 shares (Direct)

Holdings Before and After: Share Option (right to buy), 190,166 to 166,532 contracts (Direct); American Depositary Shares, 0 to 0 contracts (Direct); Ordinary Shares, 228,960 to 228,960 shares (Direct)

Footnotes (10)

1. F1. Reflects price per share in Ordinary Shares.
2. F2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
3. F3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
4. F4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 23,634 Ordinary Shares.
5. F5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
6. F6. 23,634 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 7,878 American Depositary Shares.
7. F7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
8. F8. Reflects price per share in American Depositary Shares.
9. F9. The weighted average sale price for the transaction reported was $50.7956 and the range of prices were between $50.31 and $51.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
10. F10. The weighted average sale price for the transaction reported was $51.7088, and the range of prices were between $51.32 and $52.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

Key Figures

Options exercised into Ordinary Shares: 23,634 Ordinary Shares Option exercise price: 0.3400 $ per Ordinary Share ADS sold: 7,878 American Depositary Shares +5 more

8 metrics

Options exercised into Ordinary Shares 23,634 Ordinary Shares Ordinary Shares acquired upon exercise of share option on July 14, 2026

Option exercise price 0.3400 $ per Ordinary Share Exercise price for share option partially exercised on July 14, 2026

ADS sold 7,878 American Depositary Shares Total ADS sold in open-market transactions on July 14, 2026

Weighted average sale price (ADS block 1) 50.7956 $ per ADS Weighted average price for sale of 6,278 ADS, with prices between $50.31 and $51.30

Weighted average sale price (ADS block 2) 51.7088 $ per ADS Weighted average price for sale of 1,600 ADS, with prices between $51.32 and $52.27

Ordinary Shares held after transactions 252,594 Ordinary Shares Direct Ordinary Share holdings of Xichen Lin following July 14, 2026 transactions

Ordinary Shares underlying remaining options 166,532 Ordinary Shares Number of Ordinary Shares remaining under share option after partial exercise

Option expiration date 2029-09-10 Expiration date of the share option with 0.3400 $ exercise price

Key Terms

Rule 10b5-1 trading plan, American Depositary Shares, Share Option (right to buy), weighted average sale price, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

American Depositary Shares financial

"Each American Depositary Share is convertible at any time, at the holder's election"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Share Option (right to buy) financial

"Share Option (right to buy) with an exercise price of 0.3400"

weighted average sale price financial

"The weighted average sale price for the transaction reported was $51.7088"

Vesting Commencement Date financial

"one year after July 22, 2019 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Structure Therapeutics (GPCR) CSO Xichen Lin report on July 14, 2026?

Xichen Lin exercised options for 23,634 Ordinary Shares at $0.34, converted them into 7,878 American Depositary Shares, and sold all 7,878 ADS in two open-market transactions, as well as updating remaining option holdings and share ownership.

How many Structure Therapeutics (GPCR) ADS did Xichen Lin sell and at what prices?

Lin sold a total of 7,878 American Depositary Shares, including 6,278 ADS at a weighted average price of $50.7956 and 1,600 ADS at a weighted average price of $51.7088 per ADS, with detailed price ranges disclosed for each transaction.

What are Xichen Lin’s holdings in Structure Therapeutics (GPCR) after these transactions?

After the reported transactions, Lin holds 252,594 Ordinary Shares of Structure Therapeutics directly and retains share options over 166,532 Ordinary Shares, all with an exercise price of $0.34 per share and an expiration date of September 10, 2029.

Were Xichen Lin’s sales of Structure Therapeutics (GPCR) ADS made under a Rule 10b5-1 plan?

Yes. The American Depositary Shares sold by Lin were disposed of pursuant to a Rule 10b5-1 trading plan that was entered into on March 26, 2026, indicating the sales were pre-arranged rather than discretionary market-timing decisions.

What are the key terms of Xichen Lin’s remaining share options in Structure Therapeutics (GPCR)?

Lin’s remaining share option covers 166,532 Ordinary Shares with an exercise price of $0.34 per share and an expiration date of September 10, 2029, following a vesting schedule that began on July 22, 2019 and continued in monthly installments.

How do Structure Therapeutics (GPCR) American Depositary Shares relate to Ordinary Shares?

Each American Depositary Share of Structure Therapeutics is convertible at any time, at the holder’s election, into three Ordinary Shares of the issuer, and the American Depositary Shares themselves have no expiration date according to the disclosed terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Xichen

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/14/2026		M		23,634	A	$0.34(1)	252,594	D
Ordinary Shares	07/14/2026		C		23,634(2)	D	$0	228,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$0.34(1)	07/14/2026		M			23,634	(3)	09/10/2029	Ordinary Shares	23,634	$0	166,532(4)	D
American Depositary Shares	(5)	07/14/2026		C		7,878(6)		(5)	(5)	Ordinary Shares	23,634	$0	7,878	D
American Depositary Shares	(5)	07/14/2026		S(7)			6,278	(5)	(5)	Ordinary Shares	18,834	$50.7956(8)(9)	1,600	D
American Depositary Shares	(5)	07/14/2026		S(7)			1,600	(5)	(5)	Ordinary Shares	4,800	$51.7088(8)(10)	0	D

Explanation of Responses:

1. Reflects price per share in Ordinary Shares.

2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.

3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 23,634 Ordinary Shares.

5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.

6. 23,634 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 7,878 American Depositary Shares.

7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.

8. Reflects price per share in American Depositary Shares.

9. The weighted average sale price for the transaction reported was $50.7956 and the range of prices were between $50.31 and $51.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

10. The weighted average sale price for the transaction reported was $51.7088, and the range of prices were between $51.32 and $52.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

	/s/ Jun Yoon, Attorney-in-Fact	07/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)